Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration

PLoS Genetics

Volumn 12, Issue 3, 2016, Pages

  Davis, Marie Y ^a   Trinh, Kien ^a   Thomas, Ruth E ^a   Yu, Selina ^a   Germanos, Alexandre A ^a   Whitley, Brittany N ^b   Sardi, Sergio Pablo ^c   Montine, Thomas J ^a   Pallanck, Leo J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GLUCOSIDASE; GLUCOSYLCERAMIDASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DROSOPHILA; ECTOPIC EXPRESSION; ENZYME DEFICIENCY; FEMALE; GBA1B GENE; GENE; GENE DELETION; GENE MUTATION; GLUCOCEREBROSIDASE DEFICIENCY; HOMOZYGOTE; HUMAN; LIFESPAN; MALE; MEMORY DISORDER; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UBIQUITINATION; ANIMAL; DROSOPHILA MELANOGASTER; GAUCHER DISEASE; GENETICS; LYSOSOME; METABOLISM; PARKINSON DISEASE; PATHOLOGY; PROTEINOSIS;

ALPHA-SYNUCLEIN; ANIMALS; DOPAMINERGIC NEURONS; DROSOPHILA MELANOGASTER; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; LYSOSOMES; NERVE DEGENERATION; PARKINSON DISEASE; PHENOTYPE; PROTEIN AGGREGATION, PATHOLOGICAL;

EID: 84962477435     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1005944     Document Type: Article

References (68)

1. Rosenbloom BE, Weinreb NJ, Gaucher disease: a comprehensive review. Critical reviews in oncogenesis. 2013;18(3):163–75. 23510062.
2. Sidransky E, Gaucher disease: insights from a rare Mendelian disorder. Discovery medicine. 2012;14(77):273–81. 23114583; PubMed Central PMCID: PMC4141347.
3. Sidransky E, Lopez G, The link between the GBA gene and parkinsonism. Lancet neurology. 2012;11(11):986–98. Epub 2012/10/20. doi: 10.1016/S1474-4422(12)70190-423079555.
4. Beavan MS, Schapira AH, Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Annals of medicine. 2013;45(8):511–21. Epub 2013/11/14. doi: 10.3109/07853890.2013.84900324219755.
5. Machaczka M, Rucinska M, Skotnicki AB, Jurczak W, Parkinson's syndrome preceding clinical manifestation of Gaucher's disease. Am J Hematol. 1999;61(3):216–7. Epub 1999/07/09. 10398575.
6. Tayebi N, Callahan M, Madike V, Stubblefield BK, Orvisky E, Krasnewich D, et al. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab. 2001;73(4):313–21. Epub 2001/08/18. doi: 10.1006/mgme.2001.320111509013.
7. Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology. 2006;67(5):908–10. doi: 10.1212/01.wnl.0000230215.41296.1816790605.
8. Mata IF, Samii A, Schneer SH, Roberts JW, Griffith A, Leis BC, et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Archives of neurology. 2008;65(3):379–82. doi: 10.1001/archneurol.2007.6818332251; PubMed Central PMCID: PMC2826203.
9. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. The New England journal of medicine. 2009;361(17):1651–61. Epub 2009/10/23. doi: 10.1056/NEJMoa090128119846850; PubMed Central PMCID: PMC2856322.
10. Sardi SP, Cheng SH, Shihabuddin LS, Gaucher-related synucleinopathies: The examination of sporadic neurodegeneration from a rare (disease) angle. Progress in neurobiology. 2015. doi: 10.1016/j.pneurobio.2014.12.00125573151.
11. Siebert M, Sidransky E, Westbroek W, Glucocerebrosidase is shaking up the synucleinopathies. Brain: a journal of neurology. 2014;137(Pt 5):1304–22. doi: 10.1093/brain/awu00224531622; PubMed Central PMCID: PMC3999712.
12. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302(5646):841. doi: 10.1126/science.109027814593171.
13. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004;364(9440):1167–9. doi: 10.1016/S0140-6736(04)17103-115451224.
14. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146(1):37–52. doi: 10.1016/j.cell.2011.06.00121700325; PubMed Central PMCID: PMC3132082.
15. Rothaug M, Zunke F, Mazzulli JR, Schweizer M, Altmeppen H, Lullmann-Rauch R, et al. LIMP-2 expression is critical for beta-glucocerebrosidase activity and alpha-synuclein clearance. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(43):15573–8. doi: 10.1073/pnas.140570011125316793; PubMed Central PMCID: PMC4217458.
16. Suzuki M, Fujikake N, Takeuchi T, Kohyama-Koganeya A, Nakajima K, Hirabayashi Y, et al. Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant alpha-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease. Human molecular genetics. 2015;24(23):6675–86. doi: 10.1093/hmg/ddv37226362253.
17. mod EC, Roy S, Ernst J, Kharchenko PV, Kheradpour P, Negre N, et al. Identification of functional elements and regulatory circuits by Drosophila modENCODE. Science. 2010;330(6012):1787–97. doi: 10.1126/science.119837421177974; PubMed Central PMCID: PMC3192495.
18. Chintapalli VR, Wang J, Dow JA, Using FlyAtlas to identify better Drosophila melanogaster models of human disease. Nature genetics. 2007;39(6):715–20. doi: 10.1038/ng204917534367.
19. Fergestad T, Bostwick B, Ganetzky B, Metabolic disruption in Drosophila bang-sensitive seizure mutants. Genetics. 2006;173(3):1357–64. doi: 10.1534/genetics.106.05746316648587; PubMed Central PMCID: PMC1526683.
20. Ganetzky B, Wu CF, Indirect Suppression Involving Behavioral Mutants with Altered Nerve Excitability in DROSOPHILA MELANOGASTER. Genetics. 1982;100(4):597–614. 17246073; PubMed Central PMCID: PMC1201835.
21. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science. 2001;293(5530):711–4. Epub 2001/06/16. doi: 10.1126/science.106238211408621.
22. Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, Duthie FA, et al. Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience. 2005;132(1):123–35. Epub 2005/03/23. doi: 10.1016/j.neuroscience.2004.12.02515780472.
23. Ihara R, Matsukawa K, Nagata Y, Kunugi H, Tsuji S, Chihara T, et al. RNA binding mediates neurotoxicity in the transgenic Drosophila model of TDP-43 proteinopathy. Human molecular genetics. 2013;22(22):4474–84. Epub 2013/06/28. doi: 10.1093/hmg/ddt29623804749.
24. Whitworth AJ, Theodore DA, Greene JC, Benes H, Wes PD, Pallanck LJ, Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(22):8024–9. doi: 10.1073/pnas.050107810215911761; PubMed Central PMCID: PMC1142368.
25. Trinh K, Moore K, Wes PD, Muchowski PJ, Dey J, Andrews L, et al. Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2008;28(2):465–72. doi: 10.1523/JNEUROSCI.4778-07.200818184789.
26. Simonsen A, Cumming RC, Brech A, Isakson P, Schubert DR, Finley KD, Promoting basal levels of autophagy in the nervous system enhances longevity and oxidant resistance in adult Drosophila. Autophagy. 2008;4(2):176–84. 18059160.
27. Demontis F, Perrimon N, FOXO/4E-BP signaling in Drosophila muscles regulates organism-wide proteostasis during aging. Cell. 2010;143(5):813–25. doi: 10.1016/j.cell.2010.10.00721111239; PubMed Central PMCID: PMC3066043.
28. Juhasz G, Erdi B, Sass M, Neufeld TP, Atg7-dependent autophagy promotes neuronal health, stress tolerance, and longevity but is dispensable for metamorphosis in Drosophila. Genes Dev. 2007;21(23):3061–6. doi: 10.1101/gad.160070718056421; PubMed Central PMCID: PMCPMC2081972.
29. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. The Journal of biological chemistry. 2007;282(33):24131–45. doi: 10.1074/jbc.M70282420017580304.
30. DeVorkin L, Gorski SM, Monitoring autophagic flux using Ref(2)P, the Drosophila p62 ortholog. Cold Spring Harb Protoc. 2014;2014(9):959–66. doi: 10.1101/pdb.prot08033325183816.
31. Sardi SP, Clarke J, Viel C, Chan M, Tamsett TJ, Treleaven CM, et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(9):3537–42. doi: 10.1073/pnas.122046411023297226; PubMed Central PMCID: PMC3587272.
32. Devine MJ, Gwinn K, Singleton A, Hardy J, Parkinson's disease and alpha-synuclein expression. Movement disorders: official journal of the Movement Disorder Society. 2011;26(12):2160–8. Epub 2011/09/03. doi: 10.1002/mds.2394821887711.
33. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D, Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305(5688):1292–5. doi: 10.1126/science.110173815333840.
34. Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, et al. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain: a journal of neurology. 2014;137(Pt 3):834–48. doi: 10.1093/brain/awt36724477431; PubMed Central PMCID: PMC3927701.
35. Bae EJ, Yang NY, Lee C, Lee HJ, Kim S, Sardi SP, et al. Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and alpha-synuclein aggregation. Experimental & molecular medicine. 2015;47:e153. doi: 10.1038/emm.2014.12825813221.
36. Conway KA, Harper JD, Lansbury PT, Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nature medicine. 1998;4(11):1318–20. doi: 10.1038/33119809558.
37. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949–53. doi: 10.1126/science.122715723161999; PubMed Central PMCID: PMC3552321.
38. Volpicelli-Daley LA, Luk KC, Lee VM, Addition of exogenous alpha-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-synuclein to Lewy body and Lewy neurite-like aggregates. Nature protocols. 2014;9(9):2135–46. doi: 10.1038/nprot.2014.14325122523.
39. Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, et al. Prion-like spreading of pathological alpha-synuclein in brain. Brain: a journal of neurology. 2013;136(Pt 4):1128–38. doi: 10.1093/brain/awt03723466394; PubMed Central PMCID: PMC3613715.
40. Samii A, Nutt JG, Ransom BR, Parkinson's disease. Lancet. 2004;363(9423):1783–93. doi: 10.1016/S0140-6736(04)16305-815172778.
41. Ziemssen T, Reichmann H, Non-motor dysfunction in Parkinson's disease. Parkinsonism & related disorders. 2007;13(6):323–32. doi: 10.1016/j.parkreldis.2006.12.01417349813.
42. Keatinge M, Bui H, Menke A, Chen YC, Sokol AM, Bai Q, et al. Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death. Human molecular genetics. 2015;24(23):6640–52. doi: 10.1093/hmg/ddv36926376862; PubMed Central PMCID: PMCPMC4634372.
43. Uemura N, Koike M, Ansai S, Kinoshita M, Ishikawa-Fujiwara T, Matsui H, et al. Viable neuronopathic Gaucher disease model in Medaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein. PLoS genetics. 2015;11(4):e1005065. doi: 10.1371/journal.pgen.100506525835295; PubMed Central PMCID: PMC4383526.
44. Kovacs GG, Breydo L, Green R, Kis V, Puska G, Lorincz P, et al. Intracellular processing of disease-associated alpha-synuclein in the human brain suggests prion-like cell-to-cell spread. Neurobiol Dis. 2014;69:76–92. doi: 10.1016/j.nbd.2014.05.02024878508.
45. Feany MB, Bender WW, A Drosophila model of Parkinson's disease. Nature. 2000;404(6776):394–8. doi: 10.1038/3500607410746727.
46. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. The New England journal of medicine. 2009;361(17):1651–61. Epub 2009/10/23. doi: 10.1056/NEJMoa090128119846850; PubMed Central PMCID: PMC2856322.
47. Velayati A, Yu WH, Sidransky E, The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep. 2010;10(3):190–8. Epub 2010/04/29. doi: 10.1007/s11910-010-0102-x20425034.
48. Gan-Or Z, Giladi N, Orr-Urtreger A, Differential phenotype in Parkinson's disease patients with severe versus mild GBA mutations. Brain: a journal of neurology. 2009;132(Pt 10):e125. Epub 2009/06/09. doi: 10.1093/brain/awp16119502295.
49. Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, et al. The risk of Parkinson's disease in type 1 Gaucher disease. J Inherit Metab Dis. 2010;33(2):167–73. Epub 2010/02/24. doi: 10.1007/s10545-010-9055-020177787; PubMed Central PMCID: PMC2887303.
50. Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ, Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(7):4078–83. doi: 10.1073/pnas.073755610012642658; PubMed Central PMCID: PMC153051.
51. Meulener M, Whitworth AJ, Armstrong-Gold CE, Rizzu P, Heutink P, Wes PD, et al. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr Biol. 2005;15(17):1572–7. doi: 10.1016/j.cub.2005.07.06416139213.
52. Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature. 2006;441(7097):1162–6. doi: 10.1038/nature0477916672981.
53. Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature. 2006;441(7097):1157–61. doi: 10.1038/nature0478816672980.
54. Greene JC, Whitworth AJ, Andrews LA, Parker TJ, Pallanck LJ, Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Human molecular genetics. 2005;14(6):799–811. doi: 10.1093/hmg/ddi07415689351.
55. Whitworth AJ, Wes PD, Pallanck LJ, Drosophila models pioneer a new approach to drug discovery for Parkinson's disease. Drug Discov Today. 2006;11(3–4):119–26. doi: 10.1016/S1359-6446(05)03693-716533709.
56. Tettamanti G, Bassi R, Viani P, Riboni L, Salvage pathways in glycosphingolipid metabolism. Biochimie. 2003;85(3–4):423–37. 12770781.
57. Mencarelli C, Martinez-Martinez P, Ceramide function in the brain: when a slight tilt is enough. Cellular and molecular life sciences: CMLS. 2013;70(2):181–203. doi: 10.1007/s00018-012-1038-x22729185; PubMed Central PMCID: PMC3535405.
58. Ben-David O, Futerman AH, The role of the ceramide acyl chain length in neurodegeneration: involvement of ceramide synthases. Neuromolecular medicine. 2010;12(4):341–50. doi: 10.1007/s12017-010-8114-x20502986.
59. Morales A, Lee H, Goni FM, Kolesnick R, Fernandez-Checa JC, Sphingolipids and cell death. Apoptosis: an international journal on programmed cell death. 2007;12(5):923–39. doi: 10.1007/s10495-007-0721-017294080.
60. Ishibashi Y, Kohyama-Koganeya A, Hirabayashi Y, New insights on glucosylated lipids: metabolism and functions. Biochim Biophys Acta. 2013;1831(9):1475–85. doi: 10.1016/j.bbalip.2013.06.00123770033.
61. Zhu M, Fink AL, Lipid binding inhibits alpha-synuclein fibril formation. The Journal of biological chemistry. 2003;278(19):16873–7. doi: 10.1074/jbc.M21013620012621030.
62. Fantini J, Yahi N, Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: common mechanisms in neurodegenerative diseases. Expert Rev Mol Med. 2010;12:e27. doi: 10.1017/S146239941000160220807455; PubMed Central PMCID: PMC2931503.
63. Morgado I, Garvey M, Lipids in Amyloid-beta Processing, Aggregation, and Toxicity. Adv Exp Med Biol. 2015;855:67–94. doi: 10.1007/978-3-319-17344-3_326149926.
64. Rubin GM, Spradling AC, Genetic transformation of Drosophila with transposable element vectors. Science. 1982;218(4570):348–53. 6289436.
65. Friggi-Grelin F, Coulom H, Meller M, Gomez D, Hirsh J, Birman S, Targeted gene expression in Drosophila dopaminergic cells using regulatory sequences from tyrosine hydroxylase. J Neurobiol. 2003;54(4):618–27. doi: 10.1002/neu.1018512555273.
66. Ling D, Salvaterra PM, Robust RT-qPCR data normalization: validation and selection of internal reference genes during post-experimental data analysis. PloS one. 2011;6(3):e17762. doi: 10.1371/journal.pone.001776221423626; PubMed Central PMCID: PMCPMC3058000.
67. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676–82. doi: 10.1038/nmeth.201922743772; PubMed Central PMCID: PMC3855844.
68. Ball E, Karlik CC, Beall CJ, Saville DL, Sparrow JC, Bullard B, et al. Arthrin, a myofibrillar protein of insect flight muscle, is an actin-ubiquitin conjugate. Cell. 1987;51(2):221–8. 2822254.